Brain radiation showdown: which technique saves your memory?

NCT ID NCT07505979

Not yet recruiting Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests three radiation approaches for people with six or more brain metastases from solid tumors. One group gets focused high-dose radiation (SRS), while the other two get whole-brain radiation with memory-sparing techniques plus a drug called memantine. The goal is to see which treatment best preserves cognitive function at six months. Ninety participants will be tracked with memory tests and brain scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (SRS or WBRT) plus memantine
What this could lead to: If successful, this trial could identify which radiation approach best protects memory and thinking in patients with multiple brain metastases.
What could go wrong: This is a small, early-phase trial (90 people) comparing three treatments, so results may not apply broadly. Radiation can still cause cognitive side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES FROM SOLID TUMORS

More trials for these conditions

Other studies related to the condition(s) this trial covers.